The Journal of Experimental Medicine
Fluorescence In Vivo Endomicroscopy
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article
Right arrow Full Text
Right arrow Full Text (PDF, 425K)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Körner, H.
Right arrow Articles by Smyth, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Körner, H.
Right arrow Articles by Smyth, M. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2000/1/89/ $5.00
The Journal of Experimental Medicine, Volume 191, Number 1, January 3, 2000 89-96


Original Article

Tumor Necrosis Factor Sustains the Generalized Lymphoproliferative Disorder (gld) Phenotype

Heinrich Körnera,b, Erika Cretneyd, Patricia Wilhelma,b, Janice M. Kellyd, Martin Röllinghoffb, Jonathon D. Sedgwickc, and Mark J. Smythd
a From the Interdisziplinäres Zentrum für Klinische Forschung der Universität Erlangen-Nürnberg, D-91054 Erlangen, Germany
b Institut für Klinische Mikrobiologie, Immunologie und Hygiene, D-91054 Erlangen, Germany
c DNAX Research Institute, Palo Alto, California 94304
d Laboratory of Cellular Cytoxicity, The Austin Research Institute, Heidelberg, 3084 Victoria, Australia

Correspondence to: Heinrich Körner, IZKF Nachwuchsgruppe, Institut für Klinische Mikrobiologie, Immunologie und Hygiene, Wasserturmstrasse 3-5, D-91054 Erlangen, Germany. Tel:91-31-852-2665 Fax:91-31-852- 2573 E-mail:heinrich.koerner{at}mikrobio.med.uni-erlangen.de.

Tumor necrosis factor (TNF) and Fas ligand (FasL) play major roles in the homeostasis of the peripheral immune system. This becomes dramatically obvious in the absence of a functional FasL. Mice with such a deficiency develop a profound lymphadenopathy, splenomegaly, hypergammaglobulinemia, and strain-dependent systemic autoimmune disease, and succumb to premature death. It is consequently termed generalized lymphoproliferative disorder (gld). By contrast, TNF deficiency alone does not result in a striking phenotype. Thus, we sought to determine what role TNF might play in contributing to the gld phenotype by creating C57BL/6.gld.TNF-/- mice. Contrary to the expected outcome, mice deficient for both FasL and TNF had a substantially milder gld phenotype with regard to mortality, lymphoaccumulation, germinal center formation, and hypergammaglobulinemia. To confirm these data in a strain highly permissive for the phenotype, C3H/HeJ.gld and C3H.HeJ.lpr mice were treated with a TNF-specific monoclonal antibody. This transient neutralization of TNF also resulted in a significantly attenuated lymphoproliferative phenotype. We conclude that TNF is necessary for the full manifestation of the lymphoproliferative disorder, in particular playing a critical role in lymphoaccumulation. Most importantly, absence of TNF protects gld mice against premature death.

Key Words: lymphoproliferation, apoptosis, lymphadenopathy, Fas ligand, gene targeting


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS